

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM313773

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Madison Capital Funding LLC		08/12/2014	LIMITED LIABILITY COMPANY: DELAWARE
RECEIVING PARTY DATA			
Name:	VersaPharm Incorporated		
Street Address:	1775 West Oak Parkway		
Internal Address:	Suite 800		
City:	Marietta		
State/Country:	GEORGIA		
Postal Code:	30062		
Entity Type:	CORPORATION: GEORGIA		
Name:	Covenant Pharma Inc.		
Street Address:	1775 West Oak Parkway		
Internal Address:	Suite 800		
City:	Marietta		
State/Country:	GEORGIA		
Postal Code:	30062		
Entity Type:	CORPORATION: GEORGIA		
PROPERTY NUMBERS Total: 4			
Property Type	Number	Word Mark	
Serial Number:	85071559	MYORISAN	
Registration Number:	3235289	ISONARIF	
Registration Number:	2588146	VERSAPHARM INCORPORATED	
Registration Number:	2685550	VERSAPHARM INCORPORATED X	
CORRESPONDENCE DATA			
Fax Number:	2128087897		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	2128087800		
Email:	trademarks@kelleydrye.com		
Correspondent Name:	Raxak Mahat		

OP \$115.00 85071559

TRADEMARK

Address Line 1: Kelley Drye & Warren LLP
Address Line 2: 101 Park Avenue
Address Line 4: New York, NEW YORK 10178

ATTORNEY DOCKET NUMBER: 019736-0004

NAME OF SUBMITTER: Raxak Mahat

SIGNATURE: /Raxak Mahat/

DATE SIGNED: 08/12/2014

Total Attachments: 4

source=Active_59444038_1_Madison Capital_VersaPharm-TM Release_Covenant Pharma #page1.tif
source=Active_59444038_1_Madison Capital_VersaPharm-TM Release_Covenant Pharma #page2.tif
source=Active_59444038_1_Madison Capital_VersaPharm-TM Release_Covenant Pharma #page3.tif
source=Active_59444038_1_Madison Capital_VersaPharm-TM Release_Covenant Pharma #page4.tif

**RELEASE OF GRANT OF SECURITY INTEREST
IN TRADEMARK RIGHTS**

THIS RELEASE OF SECURITY INTEREST IN TRADEMARKS (this "Release") is made as of August 12, 2014 ("Effective Date") by and between Madison Capital Funding LLC, a Delaware limited liability company, located at 30 South Wacker Drive, Suite 3700, Chicago, Illinois 60606, as Agent (in such capacity, "Agent"), to VersaPharm Incorporated, a Georgia corporation and Covenant Pharma Inc., a Georgia corporation, each located at 1775 West Oak Parkway, Suite 800, Marietta, Georgia 30062 ("Grantors").

WHEREAS, Grantors and Agent entered into that certain Amended and Restated Credit Agreement dated as of December 17, 2012 (together with all amendments and modifications, if any, from time to time thereafter made) (the "Credit Agreement");

WHEREAS, pursuant to the Credit Agreement, Grantors and Agent entered into that certain Reaffirmation Agreement dated as of December 17, 2012 (together with all amendments and modifications, if any, from time to time thereafter made) pursuant to which the Grantors reaffirmed, ratified and confirmed their respective obligations under, among other things, that certain Guarantee and Collateral Agreement dated June 3, 2011 (together with all amendments and modifications, if any, from time to time thereafter made) (the "Guarantee and Collateral Agreement");

WHEREAS, Grantors and Agent entered into the Trademark Security Agreement pursuant to the terms and conditions of that certain Guarantee and Collateral Agreement by and between Grantors and Agent dated June 3, 2011 (the "Security Agreement");

WHEREAS, pursuant to the Security Agreement, Grantors pledged and granted to Agent, for the benefit of the Agent, a continuing security interest in and to all of Grantors right, title and interest in and to all of the Trademark Collateral (as such term is defined in the Security Agreement) including, without limitation, the trademarks set forth on the Schedule attached hereto, together with the goodwill associated therewith, all proceeds thereof, and all causes of action relating thereof (collectively, the "Trademarks"); and

WHEREAS, the Security Agreement was recorded with the United States Patent and Trademark Office on June 16, 2011, at Reel 4563, Frame 0554.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Agent hereby agrees as follows:


Agent's security interest in and to all of Grantors right, title and interest in and to all of the Trademark Collateral granted pursuant to the Security Agreement is hereby terminated and released. To the extent Agent retains any such interest, Agent hereby assigns, transfers and conveys to Grantors, all of Agent's right, title and interest now owned that it may have whether by assignment or otherwise, in and to any security interest and collateral assignment in the

Trademark Collateral. Such assignment, transfer and conveyance by Agent is made without any representation or warranty (express or implied) by Agent.

* * * * *

IN WITNESS WHEREOF, Agent has caused this Release to be executed by its duly authorized representative as of the Effective Date.

MADISON CAPITAL FUNDING LLC, As Agent



Name: Faraaz Kamran

Title: Managing Director

[VERSAPHARM TM SECURITY RELEASE]

TRADEMARK
REEL: 005342 FRAME: 0151

SCHEDULE

Grantor	Trademark Application Number	Trademark Registration Number	Date of Application	Date of Registration
VersaPharm Incorporated	85071559	n/a	6/25/10	n/a
Covenant Pharma Inc.	78755383	3235289	11/16/05	4/24/07
VersaPharm Incorporated	76269614	2588146	6/1/01	7/2/02
VersaPharm Incorporated	76269637	2685550	6/1/01	2/11/03